Quidel re-launches infectious mononucleosis test
This article was originally published in Clinica
Executive Summary
Quidel has re-launched its QuickVue+ lateral flow test for infectious mononucleosis in response to "strong customer demand". The San Diego, California firm stopped manufacturing the test in August 2007 "due to a heavy investment required to maintain the production line", it told Clinica. "At the time, we had a variety of other projects that provided us with a better long-term opportunity. After completion [of these], we turned our attention back to the mono product." Infectious mononucleosis, also known as mono and glandular fever, is caused by the Epstein-Barr virus and spread via saliva. Quidel's test provides results in five minutes and detects immunoglobulin M (IgM), an antibody that appears early in the course of infection.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.